Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 09 Nov 2018
Price : $35 *
At a glance
- Drugs IDO peptide vaccine (Primary) ; Nivolumab (Primary) ; Montanide ISA-51
- Indications Malignant melanoma
- Focus Adverse reactions
- 30 Oct 2018 Planned number of patients changed from 30 to 50.
- 31 Aug 2018 Biomarkers information updated
- 22 Jan 2018 Status changed from not yet recruiting to recruiting.